Annexon said its Q2 2026 results highlighted pipeline progress, led by positive interim FORWARD data for tanruprubart in Guillain-Barré syndrome ahead of key cl

Annexon said its Q2 2026 results highlighted pipeline progress, led by positive interim FORWARD data for tanruprubart in Guillain-Barré syndrome ahead of key clinical and regulatory milestones. It also flagged further updates in geographic atrophy and autoimmune programs.